Trials / Completed
CompletedNCT03268993
Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer
A Phase 0 Study Evaluating the Systemic Bioavailability and Pharmacodynamic Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- University of Pittsburgh · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Avmacol is an over-the-counter dietary supplement containing broccoli seed and sprout extracts in tablet form, hypothesized to activate protective cellular pathways including detoxication. In this study, participants who have been curatively treatment for head and neck cancer, will take Avmacol twice a day for 3 months.
Detailed description
The broccoli seed preparation, Avmacol®, results in acute and/or sustained induction of NRF2 target gene transcripts in the oral mucosa of patients who have been curatively treated for a tobacco-related head and neck squamous cell carcinoma (HNSCC), including high grade dysplasia, carcinoma in situ, or invasive carcinoma. This study is not designed to examine the therapeutic or reparative effects of Avmacol® on premalignant lesions of the oral cavity. We will systematically assess the clinical chemopreventive potential of Avmacol® administration to patients with tobacco-related HNSCC at high risk for second primary tumor by: 1. Conducting this phase 0 clinical study to evaluate the pharmacodynamic range of NRF2 pathway activation in the oral mucosa of HNSCC patients, in response to two tolerable and bioactive doses of Avmacol®; 2. Determining whether the level of NRF2 pathway activation achieved in human oral epithelium is chemopreventive in the NQO1 murine model of environmental carcinogenesis; and 3. Analyzing specimens from the Phase 0 trial to determine whether Avmacol® induces changes in alternative biomarkers of SF chemopreventive efficacy identified in the laboratory.
Conditions
- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Head and Neck Carcinoma
- Head and Neck
- Tobacco-Related Carcinoma
- Carcinoma in Situ
- Dysplasia
- Hyperplasia
- Premalignant Lesion
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Avmacol | Avmacol is a dietary supplement available over the counter |
Timeline
- Start date
- 2018-07-27
- Primary completion
- 2019-07-22
- Completion
- 2019-07-22
- First posted
- 2017-08-31
- Last updated
- 2023-04-07
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03268993. Inclusion in this directory is not an endorsement.